Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F21%3A00013108" target="_blank" >RIV/00023736:_____/21:00013108 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/65269705:_____/21:00075860

Výsledek na webu

<a href="https://doi.org/10.1038/s41375-020-01022-2" target="_blank" >https://doi.org/10.1038/s41375-020-01022-2</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41375-020-01022-2" target="_blank" >10.1038/s41375-020-01022-2</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Popis výsledku v původním jazyce

Red blood cell transfusions (RBCT) remain the cornerstone of supportive care in lower-risk myelodysplastic syndrome (LRMDS). Transfusion dependency in LRMDS patients is associated with inferior outcomes, mainly attributed to severe bone marrow failure. However, iron toxicity, due to frequent RBCT or ineffective erythropoiesis, may be an additional negative prognostic factor. Recently, much progress has been made in unraveling the iron metabolism. The peptide hormone hepcidin is the key regulator by inhibiting iron uptake through degradation of ferroportin, a cellular iron exporter. Erythroferrone and GDF15, produced by erythroblasts, inhibit hepcidin production, which leads to increased uptake and cellular release of iron for the purpose of erythropoiesis.

Název v anglickém jazyce

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

Popis výsledku anglicky

Red blood cell transfusions (RBCT) remain the cornerstone of supportive care in lower-risk myelodysplastic syndrome (LRMDS). Transfusion dependency in LRMDS patients is associated with inferior outcomes, mainly attributed to severe bone marrow failure. However, iron toxicity, due to frequent RBCT or ineffective erythropoiesis, may be an additional negative prognostic factor. Recently, much progress has been made in unraveling the iron metabolism. The peptide hormone hepcidin is the key regulator by inhibiting iron uptake through degradation of ferroportin, a cellular iron exporter. Erythroferrone and GDF15, produced by erythroblasts, inhibit hepcidin production, which leads to increased uptake and cellular release of iron for the purpose of erythropoiesis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia

ISSN

0887-6924

e-ISSN

—

Svazek periodika

35

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

1745-1750

Kód UT WoS článku

000570816400002

EID výsledku v databázi Scopus

2-s2.0-85091002113